BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29739450)

  • 21. Subgroup and subtype-specific outcomes in adult medulloblastoma.
    Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V
    Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nomograms based on preoperative multiparametric magnetic resonance imaging for prediction of molecular subgrouping in medulloblastoma: results from a radiogenomics study of 111 patients.
    Dasgupta A; Gupta T; Pungavkar S; Shirsat N; Epari S; Chinnaswamy G; Mahajan A; Janu A; Moiyadi A; Kannan S; Krishnatry R; Sastri GJ; Jalali R
    Neuro Oncol; 2019 Jan; 21(1):115-124. PubMed ID: 29846693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem.
    Grammel D; Warmuth-Metz M; von Bueren AO; Kool M; Pietsch T; Kretzschmar HA; Rowitch DH; Rutkowski S; Pfister SM; Schüller U
    Acta Neuropathol; 2012 Apr; 123(4):601-14. PubMed ID: 22349907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy.
    Lafay-Cousin L; Smith A; Chi SN; Wells E; Madden J; Margol A; Ramaswamy V; Finlay J; Taylor MD; Dhall G; Strother D; Kieran MW; Foreman NK; Packer RJ; Bouffet E
    Pediatr Blood Cancer; 2016 Sep; 63(9):1527-34. PubMed ID: 27145464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of Ki-67 index in adult medulloblastoma after accounting for molecular subgroup: a retrospective clinical and molecular analysis.
    Zhao F; Zhang J; Li P; Zhou Q; Zhang S; Zhao C; Wang B; Yang Z; Li C; Liu P
    J Neurooncol; 2018 Sep; 139(2):333-340. PubMed ID: 29687281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model.
    Tan IL; Arifa RDN; Rallapalli H; Kana V; Lao Z; Sanghrajka RM; Sumru Bayin N; Tanne A; Wojcinski A; Korshunov A; Bhardwaj N; Merad M; Turnbull DH; Lafaille JJ; Joyner AL
    Oncogene; 2021 Jan; 40(2):396-407. PubMed ID: 33159168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicomorphological and molecular analysis of medulloblastoma and association with survival: A single tertiary care center experience.
    Badiger S; Gudipati A; Uppin M; Konatam ML; Yeramneni VK; Bhattacharjee S; Saradhi MV; Patnaik S; Irukulla M
    J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S592-S602. PubMed ID: 38384024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
    Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA
    J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
    Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin DC; Castelo-Branco P; Baskin B; Ray PN; Bouffet E; von Bueren AO; Jones DT; Northcott PA; Kool M; Sturm D; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognar L; Klekner A; Cho BK; Kim SK; Wang KC; Eberhart CG; Fevre-Montange M; Fouladi M; French PJ; Kros M; Grajkowska WA; Gupta N; Weiss WA; Hauser P; Jabado N; Jouvet A; Jung S; Kumabe T; Lach B; Leonard JR; Rubin JB; Liau LM; Massimi L; Pollack IF; Shin Ra Y; Van Meir EG; Zitterbart K; Schüller U; Hill RM; Lindsey JC; Schwalbe EC; Bailey S; Ellison DW; Hawkins C; Malkin D; Clifford SC; Korshunov A; Pfister S; Taylor MD; Tabori U
    J Clin Oncol; 2013 Aug; 31(23):2927-35. PubMed ID: 23835706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation.
    Cambruzzi E
    Childs Nerv Syst; 2018 May; 34(5):809-815. PubMed ID: 29582169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medulloblastoma molecular dissection: the way toward targeted therapy.
    Remke M; Ramaswamy V; Taylor MD
    Curr Opin Oncol; 2013 Nov; 25(6):674-81. PubMed ID: 24076581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A simplified approach using Taqman low-density array for medulloblastoma subgrouping.
    Cruzeiro GAV; Salomão KB; de Biagi CAO; Baumgartner M; Sturm D; Lira RCP; de Almeida Magalhães T; Baroni Milan M; da Silva Silveira V; Saggioro FP; de Oliveira RS; Dos Santos Klinger PH; Seidinger AL; Yunes JA; de Paula Queiroz RG; Oba-Shinjo SM; Scrideli CA; Nagahashi SMK; Tone LG; Valera ET
    Acta Neuropathol Commun; 2019 Mar; 7(1):33. PubMed ID: 30832734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroups.
    Eid AM; Heabah NAE
    J Egypt Natl Canc Inst; 2021 Feb; 33(1):6. PubMed ID: 33555447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neogenin1 is a Sonic Hedgehog target in medulloblastoma and is necessary for cell cycle progression.
    Milla LA; Arros A; Espinoza N; Remke M; Kool M; Taylor MD; Pfister SM; Wainwright BJ; Palma V
    Int J Cancer; 2014 Jan; 134(1):21-31. PubMed ID: 23775842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
    Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M
    Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.
    Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E
    J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical implications of medulloblastoma subgroups: incidence of CSF diversion surgery.
    Schneider C; Ramaswamy V; Kulkarni AV; Rutka JT; Remke M; Tabori U; Hawkins C; Bouffet E; Taylor MD
    J Neurosurg Pediatr; 2015 Mar; 15(3):236-42. PubMed ID: 25525930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
    Remke M; Hielscher T; Korshunov A; Northcott PA; Bender S; Kool M; Westermann F; Benner A; Cin H; Ryzhova M; Sturm D; Witt H; Haag D; Toedt G; Wittmann A; Schöttler A; von Bueren AO; von Deimling A; Rutkowski S; Scheurlen W; Kulozik AE; Taylor MD; Lichter P; Pfister SM
    J Clin Oncol; 2011 Oct; 29(29):3852-61. PubMed ID: 21911727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simplified Molecular Subtyping of Medulloblastoma for Reduced Cost and Improved Turnaround Time.
    Shuangshoti S; Tadadontip P; Techavichit P; Thorner PS; Shuangshoti S; Teerapakpinyo C
    Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):538-543. PubMed ID: 31343993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma.
    Bourdeaut F; Miquel C; Richer W; Grill J; Zerah M; Grison C; Pierron G; Amiel J; Krucker C; Radvanyi F; Brugieres L; Delattre O
    Pediatr Blood Cancer; 2014 Feb; 61(2):383-6. PubMed ID: 24115570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.